Management of prostate cancer with indolent biological potential: From watchful waiting to active surveillance

Harefuah

Volumn 145, Issue 10, 2006, Pages

  Leibovici, Dan ^a   Lindner, Arie ^a   Slav, Kobi ^a   Zisman, Amnon ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Active surveillance; Indolent; Prostate cancer; Watchful waiting

Indexed keywords

AGED; CANCER STAGING; DISEASE COURSE; HUMAN; MALE; MIDDLE AGED; MONITORING; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR; QUALITY OF LIFE; REVIEW;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 33947194853     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Greenle RT, Hill Harmon MB, Murray T & al, Cancer Statistics, 2001. CA Cancer J Clin, 2002; 51: 15-36.
2. Jemal A, Murray T, Ward E & al, Cancer Statistics, 2005. CA Cancer J Clin, 2005; 55: 10-30.
3. Hebrew source
4. Hemminki K, Rawal R & Bermejo JL, Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer, 2005; 113: 312-315.
5. Newcomer LM, Stanford JL, Blumenstein BA & al, Temporal trends in the rate of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol, 1997; 158: 1427-1430.
6. Johansson JE, Andren O, Andersson SO & al, Natural history of early localized prostate cancer. JAMA, 2004; 291: 2713-2719.
7. Welch HG, Schwartz LM & Woloshin S, Prostate-specific antigen levels in the United States: implications of various definitions for the abnormal. J Natl Cancer Inst, 2005; 97: 1132-1137.
8. Ho KK, Pinsky JL, Kannel WB & al, The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol, 1993; 22 (suppl A): 6A-13A.
9. Zietman AL, Tharkal H, Wilson L & al, Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol, 2001; 166: 1702-1706.
10. Albertsen PC, Hanley JA, Gleason DF & al, Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for localized prostate cancer. JAMA, 1998; 280: 975-980.
11. Albertsen PC, Hanley JA & Fine J, 20-year outcome following conservative management of clinically localized prostate cancer. JAMA, 2005; 293: 2095-2101.
12. Chodak DW, Thisted RA, Gerber GS & al, Results of conservative management of clinically localized prostate cancer. N Engl J Med, 1994; 330: 242-248.
13. Whimore WF Jr, Clinical management of prostatic cancer. An overview. Am J Clin Oncol, 1988; (11 Suppl 2): S88-S97.
14. D' Amico A V, Moul JW, Carroll PR & al, Surrogate endpoint for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst, 2003; 95: 1376-1383.
15. Ma X, Ziel-van der Made AC, Autar B & al, Targeted biallelic inactivation of PTEN in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res, 2005; 65: 5730-5739.
16. Williams K, Fernandez S, Stien X & al, Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate, 2005; 63: 369-384.
17. Shaffer DR, Vide A, Ishiwata R & al, Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Sci USA, 2005; 102: 210-215.
18. Culig Z, Steiner H, Bartsch G & al, Mechanisms of endocrine therapy-responsive and-unresponsive prostate tumors. Endocr Relat Cancer, 2005; 12: 229-244.
19. Seligson DB, Horvath S, Shi T & al, Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 2005; 435: 1262-1266.
20. Partin AW, Mangold LA, Lamm DM & al, Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001; 58: 843-848.
21. Kattan MW, Eastham JA, Wheeler TM & al, Counceling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol, 2003; 170: 1792-1797.
22. Epstein JL, Walsh PC, Carmichael M & al, Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 1994; 271: 368-374.
23. Holmberg L, Bitt-Axelson A, Helgesen F & al, A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med, 2002; 347: 781-789.
24. Bill-Axelson A, Holmberg A, Ruutu M & al, Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med, 2005; 352: 1977-1984.
25. Carter CA, Donahue T, Sun L & al, Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol, 2003; 21: 4001-4008.
26. Alibhai SMH, Naglie G, Nam R & al, Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol, 2005; 21: 3318-3327.
27. Arredondo SA, Downs TM, Lubeck DP & al, Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol, 2004; 172 (5 Pt 1): 1830-1834.
28. Hoffman RM, Hunt WC, Gilliland FD & al, Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer, 2003; 97: 1653-1662.
29. Reis F, Netto NR Jr, Rienato JA & al, The impact of prostatectomy and brachytherapy in patients with localized prostate cancer. Int Urol Nephrol, 2004; 36: 187-190.
30. Parker C, Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 2004; 5: 101-106.
31. Klotz L, Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol, 2004; 172: S48-S50.